Company Overview and News

 
Proposed acquisition of Usha Martin#39;s steel business is credit positive: Moody#39;s

4h moneycontrol
The proposed acquisition of Usha Martin's steel business by Tata Steel is credit positive, Moody's Investors Service said.
USHAMART 517146 500470 TTST TATASTEEL TATLY UHBTY

4
Has Tata Steel overpaid for Usha Martin unit?

4h moneycontrol
Tata Steel signed a definitive agreement on September 22 to buy Usha Martin’s steel unit for about Rs 4,600 crore.
517146 500228 BHUSANSTL UHBTY JSWSTEEL USHAMART 500470 TTST TATASTEEL TATLY 500235 KSL 500570 TATAMOTORS 500055 TTM

 
Usha Martin buy to diversify Tata Steel#39;s product range : Report

9h moneycontrol
Tata Steel's acquisition of Usha Martin's speciality steel business will improve the share of long steel products in its business at no additional leverage, says a report.
USHAMART 517146 500470 TTST TATASTEEL TATLY UHBTY

1
D-Street Buzz: Pharma stocks gain led by Dr Reddy#39;s Labs; HCL Tech hits new 52-week high, DHFL tanks 20%

9h moneycontrol
The Indian stock market has witnessed some handsome bounce back as the benchmark indices have regained some lost grounds this Tuesday afternoon. The Nifty50 is up 43 points and is trading at 11,o1o while the Sensex is trading higher by 176 points at 36,481.
ESL INDIANB 533452 532832 531795 535789 EICHERMOT GRUH AXB 524804 511072 JETAIRWAYS CANFINHOME YYBKY 511196 AXBA DHFL TATASTEEL TATLY 500180 IBREALEST WEIZFOREX AUROPHARMA 532617 533273 532814 532215 511288 505200 500470 532187 AXISBANK ENGINERSIN HDFCBANK 500153 503100 YESBANK ECQRY PHOENIXLTD INDUSINDBK IDKQY ATULAUTO 533264 532648 GRHFY AXBKY IBULHSGFIN 532178 OBZIY TTST OBEROIRLTY GANESHBE HDB ARBQY

 
Sensex falls over 100 points on foreign fund outflow, rising oil prices

11h freepressjournal.in
Mumbai: Benchmark indices turned volatile after opening higher Tuesday on foreign fund outflows, surging global crude oil prices, weak rupee and negative global cues. The 30-share index fell 124.63 points, or 0.34 per cent, to 36,180.39, after touching a high of 36,454.03 at the outset.
YESBANK AXB INDUSINDBK IBN 532648 YYBKY BHRQY 533278 532215 AXBKY 532454 AXBA ICICIBANK 500470 TTST 532187 TATASTEEL TATLY AXISBANK 532174 BHARTIARTL CLNDY COALINDIA

 
D-Street Buzz: IT, pharma stocks up on weak rupee led by Aurobindo Pharma, HCL Tech; RIL gains

12h moneycontrol
There is no stopping the slide in the Indian stock market as the benchmark indices have yet again opened lower amid higher crude oil prices and a falling rupee. The Nifty50 is down 48 points and is trading below 11,ooo at 10,919 while the Sensex is trading lower by 119 points at 36,185.
523768 ESL RTI RLTAY 500325 82HP TCHQY 532636 IIFL 532832 532755 539437 531795 535789 532121 SONATSOFTW BJJQY GAILF EICHERMOT RLNIY GRUH AXB 524804 511072 JETAIRWAYS CANFINHOME YYBKY 511196 TECHM AXBA DHFL BAJFINANCE TATASTEEL TATLY GAILY KOTAKBANK VSTIND IBREALEST AUROPHARMA GUJBOROS 539254 RELIANCE 532617 532215 511288 505200 509966 532221 500470 532187 IDFCBANK AXISBANK ENGINERSIN RIGD 500034 ADANITRANS YESBANK ECQRY INDUSINDBK KMBKY IDKQY ATULAUTO 533264 532648 GRHFY AXBKY IBULHSGFIN 532178 TTST ARBQY 500366 500247 ROLTA DENABANK

5
Liquidity woes roil markets

13h freepressjournal.in
Mumbai : Benchmark BSE Sensex on Monday suffered its worst single-day loss in seven months, extending its fall for a fifth day due to a meltdown in banking and auto stocks on liquidity concerns and a rout in global markets.
BAJAJ-AUTO MUTHOOTFIN 532977 533398 BHRQY 533278 511288 535789 500470 532187 HDFCBANK HEROMOTOCO LHFLY 500570 BHARTIARTL TATAMOTORS CLNDY 500253 GICHSGFIN GRUH YESBANK EDELWEISS INDUSINDBK IBN IDKQY CANFINHOME 532648 535322 GRHFY YYBKY 511196 532922 511676 REPCOHOME IBULHSGFIN 532454 500182 ICICIBANK TTST TATASTEEL TATLY LICHSGFIN HDB 532174 500180 HRTQY COALINDIA TTM

 
Usha Martin promoters seek clarity on fund use from slump sale

2018-09-24 moneycontrol
Within days of selling their speciality steel business to the Tatas, the promoters of Usha Martin, Basant and Prashant Jhawar, sought transparency from the Tatas on fund utilisation saying as of now there is no clarity on who'll get how much from the sale proceeds.
USHAMART 517146 500470 TTST TATASTEEL TATLY BHUSANSTL UHBTY 500055

 
Usha Martin rallies 15% on Tata Steel deal

2018-09-24 thehindubusinessline
Tata Steel is set to acquire the integrated one million tonne steel-making facility of Usha Martin for a cash consideration of around Rs 4,300-4,700 crore.
USHAMART 517146 500470 TTST TATASTEEL TATLY UHBTY

 
Usha Martin jumps close to 3% in early trade after deal with Tata Steel

2018-09-24 moneycontrol
Shares of Usha Martin jumped about 8 percent at open after the company signed an agreement with Tata Steel.
USHAMART 517146 500470 TTST TATASTEEL TATLY UHBTY

 
Tata Steel signs agreement to acquire Usha Martin unit

2018-09-22 moneycontrol
Tata Steel has signed agreement to acquire the steel business of Usha Martin in a deal sources put at Rs 4,600 crore.
USHAMART 517146 500470 TTST TATASTEEL TATLY 500228 UHBTY 500235 KSL JSWSTEEL

 
India Ratings affirms stable outlook to Tata Steel

2018-09-21 moneycontrol
India Ratings and Research said it has affirmed Tata Steel's long-term issuer rating at 'IND AA' with stable outlook.
RWNFF RWEOY RWNEF 500470 TTST TATASTEEL TATLY BHUSANSTL 500055

 
JSW Steel hits record high

2018-09-21 thehindubusinessline
Shares of JSW Steel today hit a life-high as the Competition Commission of India has found no adverse effect on competition from Bhushan deal. The stock hit a record high, rising as much as 2.5 per cent to Rs 427.55.
YESBANK 500470 TTST TATASTEEL TATLY 500228 BHUSANSTL 532648 YYBKY JSWSTEEL 500055

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...